[Using regulatory peptide imunofan in type 2 diabetes mellitus patients with diabetic foot syndrome].
Randomized study in people · 2009
- What was studied
- 69 people with type 2 diabetes and diabetic foot: 39 adjunctive Imunofan, 30 basic-care controls
- Main finding
- A randomized 69-person diabetic-foot comparison reported better clinical and immune outcomes with adjunctive Imunofan, but its abstract supplies no numerical treatment effect.
Reported findings and study design
A randomized 69-person diabetic-foot comparison reported better clinical and immune outcomes with adjunctive Imunofan, but its abstract supplies no numerical treatment effect.
Imunofan + basic therapy 39; basic therapy 30; type 2 diabetes with diabetic foot and retinal angiopathy.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Clinical, laboratory and quality-of-life findings | Reported improvement with adjunctive treatment | No scores, response rates or confidence intervals in the indexed abstract |
| Randomized groups | 39 adjunctive; 30 basic therapy |
Group sizes describe the design. They must not be presented as wound-healing rates or evidence of prevention of amputation.
Source for these results ↗ · Reviewed 2026-11-01
Study limitations and source details
Study limitations
- The abstract provides no numerical treatment effect, concealment or blinding details; no claim of fewer amputations follows.
- Full methods, reporting completeness and independent replication remain to be appraised.
Source details
Original journal report
Primary citation and indexed abstract reviewed through Europe PMC. Full article not appraised.
Abstract reviewed
Sources checked
Citation
Tutel'ian AV, Iakubovskaia IA, Skrypnik NV, Levedev VV. [Using regulatory peptide imunofan in type 2 diabetes mellitus patients with diabetic foot syndrome]. Terapevticheskii arkhiv · PMID 20481041